Skip to main content
锦波生物 logo

锦波生物 — Investor Relations & Filings

Ticker · 920982 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 391 across all filing types
Latest filing 2024-03-19 Audit Report / Informat…
Country CN China
Listing Beijing Stock Exchange 920982

About 锦波生物

https://www.sxjbswyy.com/

Shanxi Jinbo Bio-Pharmaceutical Co., Ltd. specializes in the research, development, and manufacturing of functional proteins through synthetic biology. The company is recognized for its industrialization of recombinant humanized collagen, specifically Type III collagen with a stable triple helix structure. Its core business encompasses the production of medical-grade biomaterials, functional skincare products, and medical devices used in aesthetics, wound healing, and gynecological health. By utilizing advanced protein engineering, the company provides biocompatible solutions designed for tissue repair and anti-aging applications. Its technical focus remains on the structural optimization and large-scale production of high-purity recombinant proteins to meet clinical and consumer health demands.

Recent filings

Filing Released Lang Actions
审计委员会对会计师事务所履行监督职责情况报告
Audit Report / Information Classification · 95% confidence The document is a report from the Audit Committee of Shanxi Jinbo Biopharmaceutical Co., Ltd. regarding the supervision of the accounting firm Zhonghui Certified Public Accountants for the year 2023. It details the audit firm's qualifications, the appointment process, communication during the audit, and the audit results including the issuance of an unqualified audit opinion on the 2023 financial statements. The document is not the audit report itself but a supervisory report on the audit firm's performance and the audit process. It does not contain the full financial statements or detailed audit results but rather an evaluation and summary of the audit firm's duties and the committee's oversight. This fits the definition of an Audit Report / Information (AR) filing, which includes standalone audit reports and information about audit processes and results, excluding full annual reports. The document length is under 5,000 characters and is a detailed report, not a mere announcement or certification, so it is not RPA or RNS. Therefore, the correct classification is AR with high confidence. FY 2023
2024-03-19 Chinese
2023年年度报告
Annual Report Classification · 100% confidence The document is titled "年度报告 2023" which translates to "Annual Report 2023" for Shanxi Jinbo Bio-Pharmaceutical Co., Ltd. It contains detailed sections typical of an annual report, including company overview, financial data and indicators, management discussion and analysis, major events, shareholder information, financing and profit distribution, board and management details, industry information, corporate governance, and full financial accounting reports. The document includes audited financial data, management certifications, and an auditor's unqualified opinion, all consistent with a comprehensive annual report. The length of the document (15,000 characters) and the detailed financial and operational data confirm it is the full annual report, not just an announcement or summary. Therefore, the correct classification is Annual Report (10-K). FY 2023
2024-03-19 Chinese
2023年度审计报告
Regulatory Filings
2024-03-19 Chinese
2023年度内部控制有效性自我评价报告
Audit Report / Information Classification · 95% confidence The document is titled as an "内部控制有效性自我评价报告" which translates to "Internal Control Effectiveness Self-Evaluation Report." It is issued by the company's board and discusses the evaluation of the company's internal control system as of December 31, 2023. The content focuses on internal control design, implementation, risk assessment, control activities, and the conclusion on the effectiveness of internal controls. It does not contain financial statements or detailed financial performance data but rather an assessment of internal controls related to financial reporting and operations. This type of document aligns with an Audit Report / Information (AR) category, which includes standalone audit reports and internal control evaluations. The document length is over 5,000 characters and contains substantive content, so it is not a mere announcement or certification. Therefore, the appropriate classification is AR with high confidence. FY 2023
2024-03-19 Chinese
关于山西锦波生物医药股份有限公司非经营性资金占用及其他关联资金往来情况的专项审核说明
Regulatory Filings
2024-03-19 Chinese
中信证券股份有限公司关于山西锦波生物医药股份有限公司2023年度募集资金存放与实际使用情况的核查意见
Regulatory Filings
2024-03-19 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.